TITLE

Chapter 14: The Myelodysplastic Syndromes

AUTHOR(S)
Ciesla, Betty
PUB. DATE
January 2007
SOURCE
Hematology in Practice;2007, p219
SOURCE TYPE
Book
DOC. TYPE
Book Chapter
ABSTRACT
Chapter 14 of the book "Hematology in Practice" is presented. It focuses on myelodysplastic syndromes (MDS). It explores the pathophysiology of MDS and the role of chromosomal abnormalities in different types of MDS. It outlines the World Health Organization's (WHO) classification of the MDS, including the specific features of the WHO classification. It also discusses prognostic factors and clinical management for MDS.
ACCESSION #
28628521

 

Related Articles

  • Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Dae-Young Kim; Je-Hwan Lee; Jung-Hee Lee; Kyoo-Hyung Lee; Yoe-Kyeoung Kim; Jae Sook Ahn; Hyeoung-Joon Kim; Inho Kim; Sung-Soo Yoon; Seonyang Park; Sung Hwa Bae; Soo-Mee Bang; Hong Ghi Lee; Ho-Jin Shin; Jae Hoon Lee; Yoo Hong Min; Jong-Ho Won; Yeung-Chul Mun; Doyeun Oh // Annals of Hematology;Jan2010, Vol. 89 Issue 1, p15 

    This study was performed to identify whether cytogenetics, International Prognostic Scoring System (IPSS), or World Health Organization Classification-Based Prognostic Scoring System are predictive of the efficacy of azacitidine in patients with myelodysplastic syndrome (MDS). We retrospectively...

  • The importance of erythroblast enumeration in myeloid neoplasia. Zeidan, Amer; Xu, Mina; Steensma, David; Zeidan, Amer M; Steensma, David P // Annals of Hematology;Feb2017, Vol. 96 Issue 2, p329 

    The article discusses the importance of enumerating and estimating blast proportion of myeloblast and erythroblast in the bone marrow cells as it provides prognosis and clinical management of patients with myelodysplastic syndromes. It mentions the 50 % rule, established by the international...

  • Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Germing, Ulrich; Aul, Carlo; Niemeyer, Charlotte M.; Haas, Rainer; Bennett, John M. // Annals of Hematology;Sep2008, Vol. 87 Issue 9, p691 

    Myelodysplastic syndromes (MDS) belong to the most frequent bone marrow diseases with a crude incidence of about 4 in 100,000 per year. The diagnosis of MDS still is mainly based on morphologic findings in blood and marrow. The new WHO classification system takes into account the medullary and...

  • Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Pleyer, Lisa; Burgstaller, Sonja; Girschikofsky, Michael; Linkesch, Werner; Stauder, Reinhard; Pfeilstocker, Michael; Schreder, Martin; Tinchon, Christoph; Sliwa, Thamer; Lang, Alois; Sperr, Wolfgang; Krippl, Peter; Geissler, Dietmar; Voskova, Daniela; Schlick, Konstantin; Thaler, Josef; Machherndl-Spandl, Sigrid; Theiler, Georg; Eckmüllner, Otto; Greil, Richard // Annals of Hematology;Nov2014, Vol. 93 Issue 11, p1825 

    Data on efficacy and safety of azacitidine in acute myeloid leukemia (AML) with >30 % bone marrow (BM) blasts are limited, and the drug can only be used off-label in these patients. We previously reported on the efficacy and safety of azacitidine in 155 AML patients treated within the Austrian...

  • Quantitative Assessment of Myeloid Nuclear Differentiation Antigen Distinguishes Myelodysplastic Syndrome From Normal Bone Marrow. McClintock-Treep, Sara A.; Briggs, Robert C.; Shults, Keith E.; Flye-Blakemore, Leanne A.; Mosse, Claudio A.; Jagasia, Madan H.; Shinar, Andrew A.; Dupont, William D.; Stelzer, Greg T.; Head, David R. // American Journal of Clinical Pathology;Mar2011, Vol. 135 Issue 3, p380 

    By using flow cytometry, we analyzed myeloid nuclear differentiation antigen (MNDA) expression in myeloid precursors in bone marrow from patients with myelodysplastic syndrome (MDS) and control samples from patients undergoing orthopedic procedures. The median percentage of MNDA-dim myeloid...

  • High Levels of Vascular Endothelial Growth Factor Protein Expression Are Associated With an Increased Risk of Transfusion Dependence in Myelodysplastic Syndromes. Gianelli, Umberto; Fracchiolla, Nicola S.; Bucciarelli, Paolo; Ferla, Valeria; Boiocchi, Leonardo; Savi, Federica; Moro, Alessia; Reda, Gianluigi; Bosari, Silvano; Cortelezzi, Agostino // American Journal of Clinical Pathology;Mar2013, Vol. 139 Issue 3, p380 

    We evaluated the prognostic significance of vascular endothelial growth factor (VEGF) protein expression in 79 bone marrow biopsy specimens of patients with myelodysplastic syndromes (MDS). VEGF levels normalized for bone marrow cellularity (VEGF index [VEGFi]) were higher in the World Health...

  • Pediatric Acute Myeloid Leukemia as Classified Using 2008 WHO Criteria. Davis, Kara L.; Marina, Neyssa; Arber, Daniel A.; Ma, Lisa; Cherry, Athena; Dahl, Gary V.; Heerema-McKenney, Amy // American Journal of Clinical Pathology;Jun2013, Vol. 139 Issue 6, p818 

    The classification of acute myeloid leukemia (AML) has evolved to the most recent World Health Organization (WHO) schema, which integrates genetic, morphologic, and prognostic data into a single system. However, this system was devised using adult data and how this system applies to a pediatric...

  • Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Atallah, E.; Nussenzveig, R.; Yin, C. C.; Bueso-Ramos, C.; Tam, C.; Manshouri, T.; Pierce, S.; Kantarjian, H.; Verstovsek, S. // Leukemia (08876924);Jun2008, Vol. 22 Issue 6, p1295 

    A letter to the editor is presented in response to the article "Prognostic Interaction Between Thrombocytosis and JAK2 V617F Mutation in the WHO Subcategories of Myelodysplastic/Myeloproliferative Disease-Unclassifiable and Refractory Anemia With Ringed Sideroblasts and Marked Thrombocytosis,"...

  • Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ravoet, Christophe; Mineur, Philippe; Robin, Valérie; Debusscher, Louisette; Bosly, André; André, Marc; Housni, Hakim; Soree, Anne; Bron, Dominique; Martiat, Philippe; Robin, Valérie; Bosly, André; André, Marc; El Housni, Hakim // Annals of Hematology;Nov2008, Vol. 87 Issue 11, p881 

    Although an activating mutation of Ras is commonly observed in myelodysplastic syndrome (MDS), the role of Ras in the natural history of MDS remains largely unknown. We prospectively studied efficiency and tolerance of lonafarnib, a compound able to inhibit Ras signalling pathway through an...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics